2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Once a month, patients with multiple myeloma received an infusion of bisphosphonates, principally to reduce osteoclastic bone resorption. Recommended infusion time for pamidronate is 2 hours in the US and 4 hours in Europe because of its potential nephrotoxicity. From 2003, a 90 mg infusion of pamidronate was provided over 1 hour to patients with no pre-existing renal impairment, in the Daily Care Unit at Uddevalla Hospital.

          Method:

          Retrospective analysis of the renal deterioration, serum calcium, and adverse effects in patients with multiple myeloma treated with 1-hour pamidronate 90 mg infusion from January 2003 to April 2007.

          Results:

          Seventy-nine patients provided valuable data. A total number of 846 infusions were given and the median number of infusion to each patient was 11. Significant creatinine elevation was seen in 7 patients (8.9%), after 19 infusions (2.2%). Renal deterioration occurred in 5 of these 7 patients, which was related to progress of the myeloma or opportunistic infections. Prevalence of infusion-related events was 0.8% and the mean total S-Ca was 0.05 mmol/L lower than the baseline.

          Conclusion:

          Few events of renal deterioration, hypocalcemia, or other adverse effects resulted from a 1-hour pamidronate 90 mg infusion for multiple myeloma patients with no pre-existing renal impairment.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          December 2008
          December 2008
          : 4
          : 6
          : 1371-1374
          Affiliations
          Department of Internal Medicine, Uddevalla Hospital, Uddevalla, Sweden
          Author notes
          Correspondence: Peter Johansson, Department of Internal Medicine, Uddevalla Hospital, Fjällvägen 7, 45180 Uddevalla, Sweden, Tel +46 522 92000, Fax +46 522 93232, Email peter.l.johansson@ 123456vgregion.se
          Article
          tcrm-4-1371
          2643118
          19337444
          © 2008 Chantzichristos et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
          Categories
          Original Research

          Medicine

          bisphosphonates, multiple myeloma, infusion time, pamidronate

          Comments

          Comment on this article